Print

HVTN 118 IPCAVD-012

A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens: Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Either Clade C gp140 Plus Adjuvant OR a Combination of Mosaic and Clade C gp140 Plus Adjuvant

Trial Details:

II Ongoing
Janssen, Janssen, HVTN/NIAID, MHRP, BIDMC, Ragon December 01, 2016
Mosaic gp140,Ad26.Mos4.HIV,gp140 C Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol + Ad26.Mos.2.Env; Protein gp140 C; Mosaic gp140
Ad26.Mos4.HIV Viral Vector - Adeno
gp140 C Protein
Mosaic gp140 Protein
aluminum phosphate
USA, Kenya, Rwanda 150
NCT02935686
https://www.clinicaltrials.gov/ct2/show/NCT02935686